Aptorum Group Limited

APM

$8.26

-14.84%

2026-08-05 15:39:12 EDT-$1.44

Healthcare

Biotechnology

NASDAQ

Inactive

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to ...

Price Action of APM

$8.26

-14.84%-$1.44

High—

Low—

52W High84.8%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Aptorum Group Limited (Nasdaq: APM) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products designed to treat conditions with significant unmet medical need. The company’s strategy emphasizes advancing a pipeline of repurposed drug candidates and other therapeutic assets across multiple programs, spanning oncology and ...Aptorum Group Limited (Nasdaq: APM) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products designed to treat conditions with significant unmet medical need. The company’s strategy emphasizes advancing a pipeline of repurposed drug candidates and other therapeutic assets across multiple programs, spanning oncology and infectious diseases, with additional preclinical work in areas such as autoimmune disease, endometriosis, obesity, and diagnostic applications. From a business perspective, Aptorum’s model is typical of early-to-mid stage life science companies: value is created by progressing assets through clinical development, generating and maintaining investor interest, and expanding partnership or financing options as programs advance. The company’s pipeline includes SACT-1 (repurposed candidate) in Phase 1 for neuroblastoma and other cancer types, and ALS-4 (repurposed small molecule) in Phase 1 for bacterial infections such as Staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. In diagnostics, Aptorum is developing RPIDD, a liquid biopsy rapid pathogen diagnostic, which is described as being in preclinical development. Aptorum also operates several additional discovery/preclinical programs, including SACT-COV19 for coronavirus disease (preclinical), and several SACT/ALS program candidates aimed at bacterial infections (including Gram-positive infections and MRSA-related indications). Beyond therapeutics, the company mentions NLS-1 (endometriosis), DLS-1 and DLS-3 programs (including autoimmune disease and NSCLC-related mutation), and CLS-1/CLS-3 for obesity, indicating a broad platform approach to therapeutic development. In terms of offerings and services, Aptorum’s profile also includes a dietary supplement product referenced as NativusWell DOI (NLS-2) for women undergoing menopause, and it states that it provides management services. While the company’s mature commercial revenues are not emphasized in the provided overview, the development pipeline, clinical trial progression, and commercialization planning are central to its cost and capital structure considerations, as such companies typically invest heavily in R&D (clinical trials, regulatory work, and related scientific activities) before generating sustained product income. Key leadership includes CEO Ian Huen. The company was founded in 2010 and is headquartered in London, United Kingdom. Overall, Aptorum positions itself as a life science innovator leveraging therapeutic repurposing and a diversified development pipeline to pursue multiple indications and potential future products under its platform of programs.ExpandCollapse

Founded

2010

Employees

CEO

Ian Huen

Full Name

Aptorum Group Limited

Sector

Healthcare

Industry

Biotechnology

ROE

6.07%

Market Cap

$0.01B

Current Ratio

0.45

ROIC

57.40%

Contact Information

https://www.aptorumgroup.com

44 20 8092 9299

116 Village Boulevard, Princeton, NJ 08540

Key Metrics of APM

Snapshot

Latest / TTM · 6 periods

Market Cap

$5.24M

ROCE

0.0%

EV / EBITDA

0.00x

+12.9% YoY

FCF Yield

-31.3%

-7.8% YoY

Cash Conversion Cycle

0.0d

Current Ratio

0.45

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of APM

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-5.16x

n/a

Debt / Equity

74.65

n/a

Current Ratio

0.45

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

High debt to equity

Calendar of APM

Upcoming

Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $3.10 · Revenue $106.80M · 1 analysts

Recent history

Jun 30, 2026
Q2 FY2026 · Results reported
EPS $-0.30 · Revenue $0.00
Dec 31, 2025
FY2025 · Annual results
EPS $-1.90 · Revenue $0.00
Jun 30, 2025
Q2 FY2025 · Results reported
EPS $-0.62 · Revenue $960817.00
Dec 31, 2024
FY2024 · Annual results
EPS $-7.80 · Revenue $0.00
Jun 30, 2024
Q2 FY2024 · Results reported
EPS $-5.00 · Revenue $0.00
Dec 31, 2023
FY2023 · Annual results
EPS $-6.20 · Revenue $431378.00

Financial Statements of APM

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-1.4M	+68.1%	+276.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-1.8M	-54.1%	-1931.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	14.9%	-6.2%	+50017.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.78x	+253.6%	-42.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$18.7M	+15.9%	-8.3%

Actual vs Estimate

A Dec 31Q Dec 31

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.90 vs 1.10	-272.7%	-0.30 vs -2.70	+88.9%
Revenue Surprise	$0 vs $65.7M	-100.0%	$0 vs $1.3M	-100.0%

Leadership Team of APM

2 executives

Name	Title	Compensation	Gender	Year Born	Status
Kwok Kuen Wong	Head of Finance	USD 92,308	Male	1956	Active
Chung Yuen Huen	Founder, Chief Executive Officer & Executive Director	—	Male	1980	Active

Recent News of APM

GlobeNewsWire7/16/2026Neutral

Aptorum Group Provides Update on DiamiR Biosciences Merger

Post-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker “NIKI”

GlobeNewsWire7/8/2026Neutral

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Alidad Mireskandari, Ph.D.

GlobeNewsWire6/22/2026Neutral

Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.

Newsfile Corp6/18/2026Neutral

Statement in Response to Silver Elephant's News Release Dated June 17, 2026

Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Andean Precious Metals Corp. (TSX: APM) (OTCQX: ANPMF) ("Andean" or the "Company") is aware of the news release issued by Silver Elephant Mining Corp. ("Silver Elephant") on June 17, 2026, regarding its filing of a Notice of Civil Claim in Vancouver, British Columbia. The allegations contained in Silver Elephant's news release and its Notice of Civil Claim are spurious and wholly without merit, and Andean strongly disagrees with Silver Elephant's characterization of the facts and circumstances described therein.

GlobeNewsWire6/10/2026Neutral

Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences

NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases.

Historical Employee Count of APM

Current

Change

+0.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	2	20-F	Mar 27, 2026	View
Dec 31, 2024	2	20-F	Apr 30, 2025	View
Dec 31, 2023	3	20-F	Apr 30, 2024	View
Dec 31, 2022	18	20-F	Apr 28, 2023	View
Dec 31, 2021	26	20-F	Apr 29, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Aptorum Group Limited